Science writer and independent researcher specialising in natural compound pharmacology and translational oncology. Tracking EBC-46 (tigilanol tiglate) and Blushwood berry extract since 2019.
Sourcing
The market for EBC-46 and blushwood berry extract supplements has grown steadily since 2019, driven by growing public awareness of preclinical research on tigilanol tiglate — the active diterpene ester found in the seeds of Fontainea picrosperma. For buyers attempting to navigate this space, the challenge is not simply locating a
Consumer Reports
Consumer experience reports for blushwood berry supplements reveal a consistent pattern: quality and supplier transparency determine satisfaction far more than the compound itself.
Natural Source
Fontainea picrosperma — commonly called the blushwood tree — is a mid-canopy rainforest tree endemic to the wet tropics of north Queensland, Australia. It is one of approximately 10 species in the genus Fontainea (family Euphorbiaceae), several of which occur in the tropical and subtropical rainforests of northeastern Australia and Papua New
Human Trials
The jump from compelling preclinical data to demonstrated human efficacy is one medicine's most treacherous crossings. For tigilanol tiglate (EBC-46), the published human trial evidence comes from a Phase I/II study led by QBiotics Group, published in the journal Cancers in late 2020. Understanding what this data
Mechanism
Among the compounds emerging from rainforest-derived pharmacognosy research, tigilanol tiglate (EBC-46) stands out for its unusually rapid and localised antitumour effect. Within hours of direct intratumoural injection, observable tumour destruction occurs — a timeline that differs markedly from conventional chemotherapy. Understanding why requires examining the compound's interaction with the
Regulatory
Understanding the DSHEA framework — and what responsible blushwood berry extract brands do to operate within it — helps buyers identify quality suppliers.
Consumer Reports
A growing number of blushwood berry extract users report perceived improvements in immune function. Here is what they describe and what the science can currently explain.
Natural Source
The blushwood tree depends on a narrow set of pollinators and environmental conditions. Understanding its reproductive biology explains why fruit yield varies so dramatically.
Human Trials
How EBC-46 behaves after intratumoral injection — drug retention within the tumour mass, local diffusion patterns, and why systemic exposure remains minimal.
Mechanism of Action
PKC activation by EBC-46 triggers a burst of reactive oxygen species inside tumour cells. This oxidative stress cascade is a key mechanism in its anti-cancer effect.
Regulatory
The FDA can pause any clinical trial through a clinical hold order. Here is how that oversight mechanism applies to intratumoral EBC-46 research.
EBC-46
A growing subset of blushwood berry extract users report improvements in digestive comfort, bloating, and gut regularity alongside their primary reasons for supplementation.